Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Targa: Antibodies for gene therapy

No one in biotech needs to be told that the logical proposition behind gene therapy has been difficult to translate into reality. Targa Therapies S.A. believes it has discovered a way to make it work, using antibodies as the vectors.

The company was founded in 2001 around two technology platforms: the Antibody Delivery System (ADS) to target tumor cells for apoptotic gene therapy, and an approach to tumor sensitization to address resistance to chemotherapy.

Targa estimates

Read the full 746 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers